Evaluation of Second-Line Chemotherapy with Docetaxel and Nedaplatin for Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus

• Miura Akinori

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Nagai Kagami

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Kojima Kazuyuki

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Yamada Hiroyuki

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Nishikage Tetsurou

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Inokuchi Mikito

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Nakajima Yasuaki

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Sekita Yoshihisa

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Ogiya Kazuo

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Tanaka Kouji

  Department of Surgery, Tokyo Medical and Dental University Hospital

• Kawano Tatsuyuki

  Department of Surgery, Tokyo Medical and Dental University Hospital

Bibliographic Information

Other Title

• 進行・再発食道癌に対するｓｅｃｏｎｄ‐ｌｉｎｅとしてのＤｏｃｅｔａｘｅｌ＋Ｎｅｄａｐｌａｔｉｎ併用療法の検討
• 進行・再発食道癌に対するsecond-lineとしてのDocetaxel+Nedaplatin併用療法の検討
• シンコウ サイハツ ショクドウガン ニ タイスル second line ト シテ ノ Docetaxel Nedaplatin ヘイヨウ リョウホウ ノ ケントウ

Abstract

We evaluated the efficacy and safety of a new combination chemotherapy including Docetaxel (TXT) and Nedaplatin (CDGP) as a second-line treatment for the advanced or recurrent esophageal carcinomas. Subsequent to administration of TXT at a dose of 60 mg for 60 minutes, CDGP was administered intravenously at a dose of 80 mg for 60 minutes. A total of nine male and one female with a median age of 65 (range 56-70) years were included and had been treated with prior chemotherapy. Prior treatments consisted of surgery and adjuvant chemoradiotherapy in 4 patients, surgery and adjuvant chemotherapy in 1 patient, chemotherapy for recurrent lesion after surgery in 3 patients, and chemotherapy alone in 2 patients. Eight patients underwent one course of treatment, 1 had two and 1 had three courses. Two PRs, 6 SDs and 2 NCs were obtained in all patients and the overall response rate was 20%. Median survival time was 170 days and median response time was 135 days. The prevailing toxicity was myelo-suppression with Grade 3 and 4 neutropenia occurring in 5 and 2 patients, respectively. The findings of this study indicated that a combination chemotherapy of TXT and CDGP is effective as a second-line treatment for advanced or recurrent esophageal cancers ; however, further investigations are needed to establish its efficacy.

Journal

• Nihon Kikan Shokudoka Gakkai Kaiho

  Nihon Kikan Shokudoka Gakkai Kaiho 56 (4), 336-342, 2005

  The Japan Broncho-esophagological Society

Keywords

• Docetaxel
• Nedaplatin
• advanced or recurrent esophageal cancer
• second-line
• chemotherapy

Details

• CRID: 1390282679989748224
• NII Article ID: 10016787026
• NII Article ID: 130004469751
• NII Book ID: AN00187474
• DOI: 10.2468/jbes.56.336
• ISSN: 18806848
• ISSN: 00290645
• NDL BIB ID: 7446226
• Web Site: http://id.ndl.go.jp/bib/7446226
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I7446226
• Web Site: https://search.jamas.or.jp/link/ui/2005231567
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed